Log in to save to my catalogue

Effects of sodium–glucose co‐transporter inhibitors on individual clinical endpoints and quality of...

Effects of sodium–glucose co‐transporter inhibitors on individual clinical endpoints and quality of...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_17c197af2fea41e4b5b93b19b86ccc46

Effects of sodium–glucose co‐transporter inhibitors on individual clinical endpoints and quality of life

About this item

Full title

Effects of sodium–glucose co‐transporter inhibitors on individual clinical endpoints and quality of life

Publisher

England: John Wiley & Sons, Inc

Journal title

ESC Heart Failure, 2025-04, Vol.12 (2), p.1271-1282

Language

English

Formats

Publication information

Publisher

England: John Wiley & Sons, Inc

More information

Scope and Contents

Contents

Aims
Sodium–glucose co‐transporter inhibitors (SGLTis) have cardiovascular protective effects. We aimed to assess the effects of SGLTis on individual hard clinical endpoints and quality of life (QoL) in patients with cardiovascular risk factors.
Methods and Results
Data was searched in PubMed, Embase, Cochrane Library and clinicaltrials.go...

Alternative Titles

Full title

Effects of sodium–glucose co‐transporter inhibitors on individual clinical endpoints and quality of life

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_17c197af2fea41e4b5b93b19b86ccc46

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_17c197af2fea41e4b5b93b19b86ccc46

Other Identifiers

ISSN

2055-5822

E-ISSN

2055-5822

DOI

10.1002/ehf2.15136

How to access this item